Prostate and colorectal adenocarcinoma are among the most common primary cancer diagnoses in the United States, with 29% of new cancer diagnoses among adult men in 2024 expected to arise from the prostate and another 15% across men and women being colorectal in origin. Given therapeutic advancements leading to improved survival, individuals with prostate cancer have the highest estimated probability of concurrent secondary primary malignancy. This represents a clinical dilemma as the treatment for each is distinct and impacted by histology, stage, and molecular findings. Herein, we describe a patient with significant comorbidities, found to have simultaneous metastatic prostate and colorectal adenocarcinomas, who achieved sustained complete remission of liver and lung metastases with a chemohormonal regimen.
The oncologist. 2025 Mar 10 [Epub]
Zane Gray, Nicholas Levonyak, Liwei Jia, Richard Ahn, Jyoti Balani, Jue Wang
Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390-8852, United States., Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX 75390-8852, United States., Department of Radiology, University of Texas Southwestern Medical Center, Dallas, TX 75390-8852, United States.